Pharmac Notification
From 1 February 2027, Pharmac will fund additional strengths of levothyroxine tablets to support more flexible and accurate dosing for people with hypothyroidism.
The change follows clinical advice that people taking levothyroxine may require precise dose adjustments, and that currently funded strengths may not always support the most convenient dosing regimen.
The new strength options may reduce the need for alternate-day dosing regimens, and the need to combine multiple tablet strengths to achieve a prescribed dose. Dose titration for people who require small dose adjustments may also be supported.
It is important to note that current funding for levothyroxine brands and strengths will continue, and there is no requirement for anyone to change brands following this decision.
In short, from 1 February 2027:
Synthroid and Eltroxin brands of levothyroxine tablets will each be funded in 25 mcg, 50 mcg, 75 mcg, and 100 mcg strengths
a new 75 mcg strength of Synthroid and Eltroxin will be funded for the first time
a new 25 mcg strength of Eltroxin will be funded for the first time.
We will continue to keep Pharmac's website updated. If you have any questions, please contact us at enquiry@pharmac.govt.nz.
Ngā mihi,
Pharmac | Te Pātaka Whaioranga | P: +0800 660 050 | www.pharmac.govt.nz
